Doxycycline in Acute Traumatic Brain Injury

• Status: Completed
• Trial end date: 2020-10-30
• Target enrollment: 0
• Participant gender: All

Summary

evaluate the impact of Doxycycline on both clinical outcome and blood levels of NSE in patients with TBI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Collaborator: Tanta University
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

1. Hospital admission in the first 24 h of injury,

2. 18 to 90 years of age and

3. Both sexes with moderate to severe traumatic brain injury (GCS score ≤ 12).

4. Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI

Exclusion Criteria:

1. Hypersensitivity to tetracyclines

2. Pregnant and breast feeding women,

3. History of autoimmune disease.

4. History of receiving chronic steroid treatment and isotretinoin,

5. Pre-existing hepatic (AST, ALT greater than 3 times the upper limit of normal) or renal failure (BUN/ Creatinine 20:1; creatinine > 2 mg/dL),

6. Known malignancies